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Case presentation
A 33-year-old male was admitted to Michael Reese Hospital and
Medical Center for evaluation of weight loss, dyspnea, and fever. He
had factor Vill-deficient hemophilia and had been chronically ill over
several months with a cough productive of scanty sputum, weight loss
of 15 Ibs, low-grade fever, and progressive dyspnea on exertion. The
medical history was notable for right total hip replacement and
splenomegaly.
Physical examination revealed a thin white male in no distress.
Temperature was 37.2°C; blood pressure, 115/80 mm Hg supine; heart
rate, 120 beats/mm; and respiratory rate, 36/mm. There were white
plaques in the mouth, bilateral axillary lymphadenopathy, and spleno-
megaly. The lungs were clear and the remainder of the examination was
within normal limits. Laboratory findings disclosed: hemoglobin, 12.5
g/dl; mean corpuscular volume, 89 jsm3; white blood cell count, 7000/
mm3 with 78% neutrophils, 4% band forms, and 7% lymphocytes; and
normal platelets. Other routine chemistry tests were normal. Urinalysis
was unremarkable. Chest x-ray was suggestive of early, patchy intersti-
tial infiltrates. An arterial blood sample obtained with the patient
breathing room air revealed a pH of 7.48; PCO2, 32mm Hg; and P02, 63
mm Hg. The patient developed a hectic fever, and treatment with
ampicillin and gentamicin was started. Pulmonary function tests
showed reduced diffusing capacity and were consistent with a mild
restrictive defect. A gallium scan revealed diffuse uptake in the lungs,
and chest x-ray showed diffuse interstitial infiltrates. On the sixth
hospital day, bronchoscopy yielded biopsy material positive for Fneu-
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rnocystis carinii. Trimethoprim-sulfamethoxazole was administered,
but was discontinued after 8 days because of leukopenia and rash.
Pentamidine isethionate, 200 mg/day intramuscularly for 7 days, pro-
duced dramatic improvement of interstitial infiltrates. The subsequent
hospital course was complicated by a recurrence of pulmonary infil-
trates, worsening dyspnea, disabling cough, severe inanition, myo-
clonus and tremors, abnormal liver function tests, hyponatremia, and
hostility and depression. Multiple cultures, including bone marrow,
revealed only Candida albicans in the sputum and urine. T-cell studies
showed a T4/T8 ratio of 0.4 (normal, 1.7—3.5), consistent with the
diagnosis of acquired immunodeficiency syndrome. A second course of
pentamidine isethionate was given for 14 days, 8 on an outpatient basis.
Following completion of the second course of treatment, the patient's
condition deteriorated and a third course of pentamidine isethionate
was started on an outpatient basis. For several days he refused to eat
and had repeated emesis. He was readmitted after a syncopal episode.
Physical examination revealed a chronically ill-appearing male in no
distress. The temperature was 36.8°C and the blood pressure was 120/80
mm Hg supine and 66/40 mm Hg standing. The corresponding heart rate
values were 68 and 72 beats/mm; the respiratory rate was 24/mm.
Positive findings included oral candidiasis and dullness at the right lung
base. No motor, sensory, or reflex abnormalities were present, with the
exception of previously known slight weakness of the right hip fiexors.
Laboratory data revealed: hemoglobin, 8.7 g/dl; mean corpuscular
volume, 93 pm3; white blood cell count, 1800/mm3 with 52% neutro-
phils, 10% band forms, and 21% lymphocytes; platelets, 97,000; serum
sodium, 135 mEq/liter; potassium, 4.4 mEq/liter; chloride, 99 mEq/liter;
carbon dioxide, 23 mmol/liter; glucose, 157 mg/dl; albumin, 3.3 g/dl;
total calcium, 8.8 mg/dI; magnesium, 1.1 mg/dl; SGOT, 182 units; and
creatine kinase (CK), 437 units, The urinalysis was unremarkable.
Chest x-ray was clear.
The clinical impression was that the patient had volume depletion and
probably esophageal candidiasis; endoscopy was negative, however.
Severe orthostatic hypotension persisted despite volume repletion.
Administration of 9-a-fluorocortisol was started on the eleventh hospi-
tal day and parenteral hyperalimentation with dextrose, vitamins, and
electrolyte solutions was initiated on the thirteenth day. Treatment with
trimethoprim-sulfamethoxazole at a low dose was restarted on the
fourteenth hospital day.
Two days later, the patient became abruptly tachypneic and had a
temperature of 38.2°C. The lungs were clear. An arterial blood sample
obtained while the patient was breathing room air revealed a pH of 7.44;
PCO2, 16 mm Hg; and P02, 90 mm Hg. Serum sodium was 135 mEq/
liter; chloride, 97 mEq/liter; carbon dioxide, 11 mmol/liter; lactate, 17.7
mEq/liter; glucose, 408 mg/dl. A serum Acetest was negative. Tobramy-
cm, cefazolin, ticarcillin, and amphotericin were administered. Hypo-
tension, oliguria and refractory lactic acidosis developed. The patient
was intubated on the eighteenth hospital day and vasopressors were
required. After more than 250 mmol of sodium bicarbonate was
administered over 6 hours, the blood pH was 7.19, lactate concentration
33.5 mEq/liter, and serum carbon dioxide 8 mmol/liter. Hemofiltration
was performed for fluid removal. On the nineteenth hospital day the
patient died.
Discussion
DR. NIcOLAOS E. MADJAS (Chief, Division of Nephrology,
New England Medical Center, and Associate Professor of
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This reversible reaction occurs in the cytosol and is catalyzed
by the enzyme lactate dehydrogenase (LDH), which is ubiqui-
tous in the cytosol. Lactate is formed when pyruvate reacts
with reduced nicotinamide adenine dinucleotide (NADH) and is
converted back to pyruvate by reactions with the oxidized
counterpart of the dinucleotide (NAD). Lactate is a metabolic
of his immunodeficiency, leukopenia, cachexia, lung injury,
and the presence of a central intravenous line. The lingering
hypotension, a known adverse effect of pentamidine isethionate
administration, might have contributed to the genesis of the
metabolic disturbance. Despite aggressive treatment, circula-
tory, renal, and respiratory failure developed; hyperlactatemia
persisted despite therapeutic efforts, including generous alkali
administration, and advanced to extreme levels during the
patient's agonal stage.
Definition of the contemporary clinical condition of lactic
acidosis is credited to Huckabee, who in 1961 pointed out that,
in addition to tissue hypoxia, hyperlactatemia might develop
under an array of other clinical circumstances [1, 2]. Nonethe-
less, tissue hypoxia secondary to circulatory failure and/or
hypoxemia constitutes the root cause of most clinical instances
of lactic acidosis.
Lactic acidosis is herein defined as the acid-base disorder,
Pyruvate concentration. Assuming no change in the other
two determinants, an increment in pyruvate concentration
should lead to a proportional increase in lactate concentration.
The cytosolic pyruvate concentration is the composite function
of a series of metabolic processes, some of which generate and
some of which consume pyruvate. The main pathway for
cellular production of pyruvate is anaerobic glycolysis (Emb-
den-Meyerhof pathway) (Fig. 1). Glycolysis occurs in the
cytosol, and its pace is controlled by the activities of three
functionally unidirectional enzymes that catalyze rate-limiting,
nonequilibrium steps in an irreversible mode: hexokinase (HK),
6-phosphofructokinase (PFK), and pyruvate kinase (PK). Dif-
ferent enzymes are required to catalyze these nonequilibrium
reactions in the "reverse" direction. ATP is an allosteric
inhibitor of the PFK reaction; thus, when ATP stores are
reduced, flux through this reaction is augmented and the rate of
glycolysis is increased. A key step in glycolysis is the oxidation
of glyceraldehyde 3-phosphate during which NAD is con-
sumed and converted to NADH. Provision of NAD therefore
is essential to the maintenance of glycolysis. Anaerobic tissues
under normal conditions and aerobic tissues under hypoxic
conditions replenish NAD stores by the cytosolic conversion
of pyruvate to lactate (Equation 1). On the other hand, aerobic
tissues under normal conditions regenerate NAD largely via
mitochondrial oxidative reactions. Because the inner mitochon-
drial membrane is impermeable to both NADH and NAD,
reoxidation of cytosolic NADH in aerobic tissues is accom-
plished indirectly via transmitochondrial substrate "shuttles."
In essence, an oxidized substrate reacts with NADH in the
Medicine, Tufts University School of Medicine, Boston, Massa-
chusetts): The terminal phase of the acquired immunodeficien-
cy syndrome in this unfortunate young man illustrates several
prototypic features of what in my opinion represented lactic
acidosis in association with sepsis. Severe hyperlactatemia
accompanied by alkalemia, rather than acidemia, developed
along with the abrupt onset of pyrexia and hyperventilation. In
all probability, gram-negative or, less likely, fungal sepsis was
the culprit. The patient was at very high risk for sepsis in view
end-product, its only metabolic fate being oxidation back to
pyruvate. The equilibrium of Equation 1 favors the formation of
lactate; thus, under normal conditions the concentration of
lactate is approximately tenfold greater than that of pyruvate.
Of the two optical isomers, L(+)-lactate is the natural form in
mammals; LDH is stereospecific for the L(+)-lactate reaction
and does not catalyze the processing of the levorotatory enan-
tiomer D(—)-lactate.
Lactate production
The presence of the enzyme LDH in sufficient quantities in
the cytosol ensures the near-equilibrium position of Equation 1.
Recasting Equation ito highlight the equilibrium concentration
of lactate yields Equation 2:
[NADH] +[Lactate] = Keq x [pyruvate] [NAD] X [H ] (2)
where Keq is the equilibrium constant of the LDH reaction and
[H] refers to the intracellular (cytosolic) hydrogen ion concen-
tration. Consequently, the cytosolic concentration of lactate
can be viewed as being determined by three variables: the
concentration of pyruvate; the [NADH]/[NAD] ratio, other-
wise referred to as the redox (reductionloxidation) state; and
the intracellular hydrogen ion concentration.
originating from accumulation of lactic acid in the body fluids,
that is manifest by a plasma lactate concentration of at least 5
mEq/liter. Such an accumulation reflects disruption of the
normal balance between production and utilization of lactic acid
and could result from its overproduction, underutilization, or
both. Lactic acidosis is probably the most common cause of
metabolic acidosis in hospitalized patients. New knowledge
about the biochemistry and regulation of lactate metabolism
have allowed a better understanding of the pathophysiology of
the clinical disorder. Regretfully, progress in treatment has not
kept pace, and all too often the development of lactic acidosis
heralds a fatal outcome, as in the patient presented today.
Comprehensive treatises of various aspects of lactic acidosis
have been published recently [3—7]. In this Forum, I will
present an overview of the topic, highlighting recent advances
in the field.
Lactate metabolism
Metabolically produced lactate is accompanied by the gener-
ation of an equivalent number of protons that are released into
the body fluids. These protons, which are titrated by bicarbon-
ate and non-bicarbonate body buffers, acidify the intracellular
and extracellular environments. By contrast, metabolic remov-
al of lactate consumes an equivalent number of hydrogen ions,
and thus replenishes the body's alkali reserve.
In this section, I will present a brief account of the biochemi-
cal and regulatory aspects of lactate production and utilization.
The sole biochemical reaction that generates or consumes
lactate in the organism is illustrated by Equation 1:
LDH
CH3COCOO + NADH + H CH3CH(OH)C00 + NAD
(pyruvate) lactate) (1)
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cytosol, having converted thereby to its reduced form; this form
is transported into the mitochondrion where it is subsequently
oxidized by the electron-transfer chain. The end result is the
effective transport of hydrogen ions, referred to as reducing
equivalents, across the mitochondrial membrane and the reoxi-
dation of cytosolic NADH. The two best-studied such systems
are the malate/aspartate shuttle and the glycerol phosphate
shuttle. Virtually all body tissues are equipped for glycolysis,
but particularly high rates are observed in brain, skeletal
muscle, heart, and intestinal mucosa. An additional, although
quantitatively smaller, source of pyruvate is the transamination
of alanine (released from muscle and small intestine) by the
enzyme alanine aminotransferase (AAT), a reaction that occurs
virtually exclusively in the liver. Finally, in the kidney, pyru-
vate is formed from the metabolism of the carbon skeleton of
glutamine (aipha-ketoglutarate) following removal of the amide
and amino nitrogen groups of glutamine in the process of
ammoniagenesis,
On the other hand, consumption of pyruvate in aerobic
tissues under normal conditions occurs by means of two
oxidative mitochondrial pathways and follows the transport of
pyruvate across the mitochondrial membrane (Fig. 1). The first
of these is oxidative decarboxylation to acetyl-coenzyme A
(acetyl-CoA), a reaction catalyzed by a complex of three
enzymes that are collectively referred to as pyruvate dehydro-
genase (PDH) and that require a continuous supply of NAD.
The PDH reaction is a nonequilibrium reaction that commits
pyruvate to acetyl-CoA; that is, there is no way that acetyl-CoA
can be converted back to pyruvate. The resultant acetyl-CoA
can enter the tricarboxylic acid (TCA) cycle and the electron
transfer/oxidative phosphorylation pathway for complete oxi-
dation to CO2 and water, or it can be utilized in various
biosynthetic pathways (fatty acids, ketone bodies, cholesterol,
steroid hormones, acetylcholine). The second aerobic mito-
chondrial pathway for pyruvate is gluconeogenesis, that is, the
synthesis of glucose or glycogen, a process occurring exclusive-
ly in the liver and the renal cortex. It is important to recognize
that gluconeogenesis is not a mere reversal of glycolysis; as I
have noted, three glycolytic reactions (HK, PFK, and PK) are
irreversibly catalyzed only in the "forward" direction. As
Figure 1 illustrates, synthesis of glucose from pyruvate (as well
as from lactate and alanine) depends on bypassing these key,
nonequilibrium reactions, The first step in this process, conver-
sion of pyruvate to phosphoenolpyruvate, involves two compo-
nents: (1) carboxylation of pyruvate to oxaloacetate within
mitochondria, a process catalyzed by pyruvate carboxylase
(PC); and (2) cytosolic conversion of oxaloacetate to phospho-
enolpyruvate, a process catalyzed by the enzyme phosphoenol-
pyruvate carboxykinase (PEPCK). Both reactions require ATP.
The two additional steps requiring specific catalysis are affected
by fructose-bisphosphatase (FBPase) and glucose-6-phospha-
tase (G-6-Pase). As is the case for the reactions unique to
Phosphoenolpyruvate Et1cDl5S
________
,—.- Alaninecarboxykinase Phosphoenolpyruvate ..- ianine
Pyruvate kinase aminotransferase
________
-"ctate dehydrogenase(cysoD PYRUVATE - LACTATE
Pyruvat)ruvate dehydrogenase
—— __—
CMitochondrio7) carboxylase Acetyl-C0A
Biosynthetic pathwaysOxaloacetate
Cholesterol, Steroid hormones
Fatty acids, Ketone bodies4 TCA
lcvcve0trate Acetyicholine Fig. 1. Metabolic pathways of glycolysis andgluconeo genesis.
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glycolysis, all those unique to gluconeogenesis are irreversible
(that is, functionally unidirectional); thus, they constitute the
rate-limiting steps of the gluconeogenesis pathway.
Formation of pyruvate (via the PK reaction) completes the
segment of the glycolytic pathway that is common to both
anaerobic and aerobic metabolism. The conversion of one
molecule of glucose to pyruvate or lactate is associated with the
net production of two molecules of ATP. The subsequent
aerobic oxidation of pyruvate generates 36 additional molecules
of ATP, for a total of 38 molecules per completely oxidized
molecule of glucose.
Impaired mitochondrial oxidative function, as occurs in hy-
poxic states, leads to accumulation of pyruvate in the cytosol
and thus to increased lactate production. The accumulation of
pyruvate reflects both overproduction of pyruvate and reduced
utilization of pyruvate through its two pathways (note the
NAD dependence of the PDH reaction and the ATP require-
ment of the PC and PEPCK reactions). The former occurs
because a reduced supply of ATP to the cytosol stimulates the
PFK reaction and results in augmented glycolysis (Fig. 2). As
noted, ATP constitutes a potent external regulator of the PFK
reaction. During anaerobic conditions, glycolysis becomes the
main source of energy for the organism; despite the prevailing
mitochondrial dysfunction, continuation of glycolysis (via oxi-
dation of glyceraldehyde 3-phosphate) is assured by cytosolic
regeneration of NAD via the conversion of pyruvate to
lactate. Thus increased lactate production represents the toll
paid by the organism to maintain energy generation during
anaerobiosis.
The [NADH]/[NAD] ratio. This ratio is a measure of the
redox state of cytosolic pyridine nucleotides. The ratio is
affected by the activity of the various cytosolic dehydrogenases
that employ pyridine nucleotides for transferring H (mainly
during the processes of glycolysis and gluconeogenesis), but in
mitochondria-containing cells it is largely determined by the
rate of mitochondrial oxidative reactions; NADH is oxidized to
NAD by the electron-transfer chain, which is coupled to
oxidative phosphorylation. Suppression of mitochondrial func-
tion through decreased oxygen availability or other mechanisms
leads to reduced availability of NAD within the cytosol; as
Equation 2 indicates, the resultant increase in the [NADH]/
[NAD] ratio shifts the equilibrium of the LDH reaction toward
lactate (Fig. 2).
Intracellular [it. According to Equation 2 and barring any
changes in pyruvate concentration and redox state, an incre-
ment in intracellular [H] should lead to increased lactate
concentration in the cytosol. In isolated tissue preparations,
however, this direct effect of intracellular [H] is ovemden by
pH-mediated effects on PFK [8] and thus on pyruvate produc-
tion (Fig. 1). Strong evidence indicates that the activity of PFK
is inhibited by intracellular acidosis and stimulated by intracel-
lular alkalosis; consequently, in tissue preparations, lactic acid
production falls during acidosis and increases during alkalosis
[9—13]. These effects of intracellular [H] on the glycolytic rate
and on lactate production have been demonstrated during
aerobiosis as well as during anaerobiosis and may well serve
an important homeostatic function. Under conditions of tissue
hypoxia, stimulation of glycolysis leads to augmented lactic
acid production with a resultant decrement in intracellular PH;
the acidosis in turn inhibits glycolysis and lactic acid production
0,,,,ENADH1ADP [NAD
Acetyl-CoA
— Oxaloacetate
G Citrate
Fig. 2. Mechanism of hypoxia-induced accumulation of lactate.
and thus moderates the acidification of the intracellular milieu.
Conversely, this servomechanism blunts the increment in intra-
cellular pH by augmenting lactic acid production during alkalo-
sis [4, 9, 11, 14]. Acidosis and alkalosis thus influence lactic
acid production in the direction of minimizing the acid-base
disruption. Given the ubiquity of the glycolytic process in
mammalian tissues, the cellular machinery may well employ
pH-regulated production of lactic acid (and other organic acids)
to buffer fluctuations in the prevailing pH, thereby maintaining
a measure of stability in intracellular as well as extracellular
domains [4, 9, 11, 12].
In-vivo observations on the composition of extracellular fluid
corroborate the existence of such a negative feedback mecha-
nism between net lactate production under basal or stimulated
conditions and acidity of body fluids. Several investigators have
documented that plasma lactate concentration falls during acute
respiratory acidosis, thus contributing a small component to the
whole body's buffer response [15—19]. In addition, small decre-
ments in plasma lactate have been observed in acute and
chronic metabolic acidosis [20, 21]. On the other hand, small
rises in plasma lactate concentration occur during acute respira-
tory or metabolic alkalosis [4, 9, 15, 16, 22—28]; however, any
tendency for a substantial increase is probably tempered by
augmented lactate utilization. Whereas plasma lactate concen-
tration is within normal limits during chronic hypocapnia even
in the presence of associated hypoxemia [29—34], a mild eleva-
tion in lactate persists in chronic metabolic alkalosis [21, 35].
An additional increment in plasma lactate is observed when
acute or chronic hypocapnia is superimposed on chronic meta-
bolic alkalosis [36].
Several recent lines of evidence lend strong support to such a
homeostatic system of net lactic acid production under condi-
tions of stimulated synthesis. Acute hypercapnia produced by
elevating FiCO2 resulted in marked suppression of exercise-
induced hyperlactatemia in volunteer subjects [37—40]. Similar-
ly, administration of either NH4CI or NaHCO3 led to substan-
tial suppression or augmentation, respectively, of the hyperlac-
tatemia of exercise [39, 41]. Muscle lactate concentration and
glycogen depletion were less in individuals ingesting NH4C1
than in those given NaHCO3. In an experimental model of
To Gluconeogenesis
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Glucose
ATP
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hypoxemia-induced lactic acidosis in the rat [42], superimposi-
tion of either mild respiratory acidosis (PaCO2, 59 mm Hg) or
HCI-induced metabolic acidosis (sufficient to decrease pH from
7.27 to only 7.23) resulted in a dramatic blunting of the rise of
blood lactate; by contrast, superimposition of respiratory alka-
losis (PaCO2, 15 mm Hg) led to an exaggerated rise in blood
lactate in the hypoxic animals. Moreover, findings in patients
with malignancy-induced chronic lactic acidosis [43, 44] as well
as extensive experience with experimental models of hypoxic
and nonhypoxic lactic acidosis {45—52] clearly demonstrates
that bicarbonate administration augments lactate production
and blood lactate levels.
These observations are in full accord with previous findings
in fasting obese humans, another state of enhanced endogenous
acid release, which revealed an exquisite sensitivity of ketoacid
production to chronic mild changes in systemic pH produced by
acid or alkali ingestion [12, 53, 54]; a fall in pH suppressed and a
rise increased ketoacid production. A similar effect has been
observed on the degree of ketonuria in patients with diabetes
mellitus [55, 56]. These clinical observations are amplified
further by the demonstration of remarkable responsiveness of
ketoacid production to acute changes in pH when HC1 or
NaHCO3 is infused into rats or humans [57—59].
Taken together, these findings suggest the existence of a
more generalized homeostatic system that regulates endoge-
nous organic acid production via changes in systemic pH [12].
What is truly remarkable is the impressive responsiveness of
this system and the magnitude of the change elicited by
relatively small deviations in extracellular pH during probing
experimental maneuvers, Obviously, it would be of great inter-
est to apply modern noninvasive technology to monitor the
response of intracellular acidity to these relatively modest
extracellular changes.
The role of this negative feedback system in the pathogenesis
and evolution of clinical lactic acidosis is uncertain, and it
represents an exciting area for future investigation. Such a
system might be crucial to survival during maximal exercise, a
state characterized by marked hyperlactatemia and severe
extracellular and intracellular acidosis [60, 61]. On the other
hand, this servomechanism is apparently overridden in cases of
severe lactic acidosis. Indeed, in hypoxic lactic acidosis, al-
though the prevailing acidemia can exert an inhibitory effect on
the magnitude of the evolving metabolic derangement, the
acidemia eventually proves impotent in preventing escalation to
extreme hyperlactatemia. It appears that any inhibitory effect of
acidemia is simply overridden by the hypoxic drive to augment-
ed lactate production. Equally uncertain is whether a clinically
relevant interaction exists between this servomechanism and
pH-mediated alterations in hepatic and renal gluconeogenesis
(and, thus, lactate uptake).
Lactate utilization
As I already have noted, the sole pathway for lactate utiliza-
tion is conversion back to pyruvate, its oxidized counterpart
(Equation 1). Consequently, metabolic removal of lactate is
equivalent to the metabolic removal of pyruvate. I will examine
the factors that influence lactate uptake and utilization in a
moment.
Lactate is freely filtered at the glomerulus. At low concentra-
tions it is reabsorbed virtually completely in the proximal
tubule. Under conditions of hyperlactatemia, renal excretion
contributes to lactate removal, the renal threshold for lactate
excretion being approximately 5 to 6 mEqlliter [20, 62]. In lactic
acid-loading experiments in humans, rats, and sheep, renal
lactate excretion accounted for less than 1.2% of the infused
load [20, 62, 63]. In general, lactate excretion represents a small
fraction of total lactate uptake by the kidney.
Physiology and quantitative aspects of lactate metabolism
Plasma lactate concentration is normally in the range of 1
mEqlliter and that of pyruvate about 0.1 mEqlliter. The normal
ratio of these two substances (known as the LIP ratio) is
approximately 10:1. Obviously, the stability of plasma lactate
concentration implies a precise equivalence between the proc-
ess of releasing lactate to, and that of removing lactate from, the
extracellular compartment. The average basal turnover rate in
normal humans has been estimated at about 20 mEqlkglday
with a range of 15 to 25 mEqlkglday [3, 6, 7, 63—66]. This
amounts to approximately 1400 mEqlday per 70 kg subject or
approximately 1 mEqlmin. Such estimates have been obtained
through a variety of techniques including the disappearance of
infused lactate, measurements of blood flow and arteriovenous
differences for lactate across tissue beds, extrapolations from
in-vitro incubation data, and the kinetics of infused isotopically
labeled lactate. Methodologic limitations make available esti-
mates gross approximations at best. Estimates of the apparent
volume of distribution of lactate range from 270 to 340 mL/kg in
humans [63, 67] and about 360 mllkg in the rat [20]. Unfortu-
nately, available information on quantitative aspects of lactate
production and utilization by humans in health and disease is
quite limited. Considerably more information is available from
studies in experimental animals.
Although all tissues produce lactate during the course of
glycolysis, only some of them contribute substantial quantities
to the extracellular fluid under normal aerobic circumstances.
Table 1 lists the lactate-producing tissues. Whereas the renal
medulla normally produces lactate in spite of an adequate
substrate and oxygen supply, the renal cortex has a high rate of
oxidative metabolism and lactate utilization [68]. Erythrocytes
are obligatory producers of lactate because, in the absence of
mitochondria, they lack the apparatus for the metabolic proc-
essing of pyruvate. During exercise, skeletal muscle is the
major source of circulating lactate. The maximal rates of lactate
production by various tissues remain unknown. Yet estimates
from individuals undergoing short bursts of maximal exercise or
having a grand-mal seizure indicate that lactate production can
increase by several hundredfold [4, 7, 69]. Under hypoxic
conditions, virtually all tissues can release lactate into the
circulation. Indeed, during severe hypoxia and acidosis, even
the liver—the predominant consumer of lactate under normal
conditions—can add lactate to the blood [70, 71]; obviously,
such a transition from net utilization of lactate to net production
is an ominous sign for the organism.
Liver and renal cortex, the major lactate-consuming organs,
can use lactate (via pyruvate) as a substrate for gluconeogenesis
and can oxidize it to CO2 and water. Animal studies indicate
that of the two pathways, gluconeogenesis is the primary mode
of lactate processing in the liver. On the other hand, in the
kidney the fraction of lactate that is extracted and converted to
glucose as opposed to being oxidized remains unclear; variable
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Table 1. Lactate-producing and -consuming tissues
under basal conditions
Producers Consumers
Skin Liver
Erythrocytes Renal cortex
Brain Heart
Skeletal muscle Salivary glands (?)
Intestinal mucosa
Leukocytes
Platelets
Renal medulla
Tissues of the eye (cornea, lens, retina)
results have been obtained depending on the experimental
conditions employed. Available evidence suggests that about
50% of the renal lactate uptake in the rat and dog is oxidized
[11, 21, 72, 731. Although the interorgan apportioning of lactate
utilization remains poorly defined, the relative contribution of
the various organs to lactate uptake varies widely according to
the prevailing conditions (for example, basal state, exogenous
infusions of lactate at rest, vigorous exercise). Estimates for the
fractional contribution of the liver to the total basal lactate load
in humans vary widely, ranging from 30% to 70%; 50% is
probably a reasonable figure [7, 74, 75]. Studies utilizing lactic
acid loading in rats and sheep have estimated that the kidney
extracts approximately 20% to 30% of the load [20, 62, 761.
Notably, the liver has a large reserve capacity for lactate
metabolism that is estimated to be higher than the basal rate by
severalfold [771. Hepatic uptake of lactate exhibits marked
concentration dependence [15, 62]. Recent lactate-loading ex-
periments in sheep suggest that hepatic lactate uptake is a
saturable process with second-order (Michaelis-Menten) kinet-
ics [62]; whereas the basal rate of hepatic lactate removal
averaged 0.57 mEq.kg°75.h', the Vmax was estimated at 5.72
mEq.kg°75.h', and the Km at 3.06 mEq/liter. Studies in the
perfused rat liver have shown saturation of uptake at a plasma
lactate concentration of approximately 4 mEqlliter [6]. Obser-
vations in humans suggest that during mild exercise (about 30%
to 60% of maximum 02 uptake, with plasma lactate levels up to
2.3 mEqfliter) hepatic lactate uptake is augmented in proportion
to the load [78—80]; in contrast, hepatic lactate uptake does not
change or even can decrease markedly during strenuous exer-
cise [74, 81]. Despite the prevailing severe hyperlactatemia
during maximal exercise, lactate uptake probably is suppressed
by the marked diminution in hepatic blood flow that is known to
occur; an additional suppressive role might be exerted by the
existing, often severe, acidosis [15, 64, 70, 82—86]. Although the
hepatic functional reserve for lactate removal is well docu-
mented, the fact that hyperlactatemia develops during even
mild exercise indicates that the liver (as well as other lactate-
consuming sites) cannot keep pace acutely with lactate-produc-
ing organs; that is, lactate production at least transiently
outstrips utilization.
Similarly, renal consumption of lactate is augmented in
hyperlactatemia, thus contributing to the organism's reserve
capacity (20, 72); the excess lactate enters both oxidative and
biosynthetic pathways [87]. As I already have noted, renal
excretion contributes to lactate removal under such circum-
stances. In response to an exogenous lactic acid load in the rat
and at a plasma lactate concentration of 10 mEqlliter, renal
lactate excretion accounted for approximately 12% of the
cumulative renal contribution to lactate removal (the latter
being about 25% to 30% of the administered load) [20]. During
hyperlactatemia the heart's contribution to lactate removal also
increases [88]. Under these conditions, the lung can be involved
in lactate utilization [89].
Although normally a lactate-producing organ, resting skeletal
muscle also can extract lactate from the blood—and use it
primarily as fuel for oxidation—during hyperlactatemia pro-
duced by exogenous infusion or by exercise of regional muscle
groups [67, 90—92]. Indeed, several studies have shown conver-
sion from lactate output to lactate uptake by resting skeletal
muscle following an infusion of a lactic acid load, with an
estimated 25% to 35% of the load taken up by muscle [62, 67,
90, 93]. Under such circumstances, skeletal muscle can dispose
of more of the lactate load than does the liver [62, 90]. Whereas
saturation of hepatic lactate uptake during relatively mild
increases in lactate level have been documented [6, 62], one
study reported no saturation of extrasplanchnic lactate uptake
even at the highest plasma lactate concentration, 20 mEqlliter
[62]. In fact, deductions drawn from studies in the isolated
perfused rat hind limb, which showed a linear increase in
muscle lactate uptake with perfusate concentrations up to 27
mEqlliter [94], suggest that the liver may contribute in only a
small way to lactate removal during recovery from maximal
exercise. Further, the rate of plasma lactate recovery was
augmented if the subject continued exercising at a submaximal
level rather than resting; this observation lends strong support
to the importance of skeletal muscle in extracting lactate under
such circumstances [81]. Limited clinical data suggest a com-
pensatory increase in lactate uptake by skeletal muscle when
hepatic lactate uptake is deranged [95]. Nonetheless, the contri-
bution of skeletal muscle to lactate utilization during clinical
lactic acidosis remains a matter of considerable debate [3, 6, 7,
64, 67].
The importance of the liver as a lactate-consuming organ is
exemplified by observations after functional hepatectomy in the
diabetic dog. Functional hepatectomy was produced by divert-
ing the portal circulation to the inferior vena cava and ligating
the hepatic artery. Although lactate production due to surgical
stress might have contributed to acidosis, 2 and 3 hours
following the procedure the plasma lactate increased from a
mean control value of 1.4 mEq/liter to average values of 6.0 and
10.7 mEq/liter, respectively; corresponding values for blood pH
were 7.20 and 7.13 (mean control value, 7.42) [96].
Turning to the contribution of the kidney to lactate disposal,
removal of an exogenous lactic acid load was slower in rats
subjected to bilateral nephrectomy as compared with animals
subjected to a sham operation; lactate elimination hall-life
averaged 5.3 minutes, and blood clearance for lactate (at a
plasma concentration of 10 mEq/liter) was 45.3 mllmin/kg in
sham-operated animals; the corresponding values were 7.1
minutes and 32 mllmin/kg in animals with bilateral nephrectomy
[20]. Overall, nephrectomy resulted in approximately a 30%
slowing of absolute lactate removal following an intravenous
lactic acid load [20].
From the standpoint of the whole organism's economy,
therefore, tissues with glycolytic activity under normal aerobic
conditions metabolize glucose to lactate and relinquish it into
the circulation. In turn, lactate is extracted by the liver and
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into the body fluids must be removed. This task is achieved
during the metabolism of lactate via the two oxidative path-
ways. When the liver and the renal cortex reconvert lactate to
glucose during gluconeogenesis, Equation 5 is reversed and a
number of protons equivalent to the number of lactate ions
consumed is removed from the body fluids (Equation 6):
2CH3CH(OH)C00 + 2W — C6H1206 (6)
(lactate) (glucose)
Gluconeogenesis is an energy-requiring process and consumes
ATP and GTP; the aerobic repletion of these high-energy
____________________________
phosphate groups produces the net utilization of protons during
gluconeogenesis [97—99]. Similarly, during the combustion of
lactate to CO2 and water, an equivalent number of protons are
abstracted from the body fluids (Equation 7):
CH3CH(OH)C00 + H + 302 —* 3C02 + 3H20 (7)
In actuality, consumption of the proton occurs during aerobic
mitochondrial ATP synthesis, which may be considered the
reverse of ATP hydrolysis [97—99].
In the overall scheme, protons are generated in the cytosol
via hydrolysis of synthesized ATP and are consumed in the
mitochondria via aerobic reconstitution of high-energy phos-
phate groups. The recapturing by the liver, and secondarily by
the kidney, of protons freed during glycolysis allows for regen-
eration of bicarbonate and back-titration of the nonbicarbonate
buffers, so that no net input of hydrogen ion to body fluids
occurs and acid-base balance remains undisturbed. In this
sense, lactic acidosis is generated whenever an imbalance
between ATP hydrolysis and ATP generation occurs, and
results in a net gain of hydrogen ions by the body fluids.
The importance of disposing of the protons produced during
glycolysis for the maintenance of acid-base equilibrium can be
better appreciated when its magnitude—that is, 15 to 25 mEq of
H/kgfday under basal conditions, as much as the lactate
produced—is contrasted with the magnitude of net acid excre-
tion by the kidney, approximately 1 mEq of H/kg!day. More-
over, under conditions of lactate overproduction, an even
greater burden is placed on the liver and the kidney to maintain
acid-base homeostasis. It is apparent therefore that from an
acid-base perspective, the liver plays a pivotal, albeit not
widely appreciated, role in ensuring the daily miracle of the
organism's survival. This analysis is a sobering reminder to
nephrologists, who usually are possessed by a nephrocentric
(3) view of acid-base balance.
Pat ho genesis of lactic acidosis
Lactic acidosis is generated whenever the production of
(4) lactic acid outstrips its utilization. The result of such animbalance is evidenced by the accumulation of lactate in the
circulation, often in the company of hypobicarbonatemia and
acidemia. From a theoretical standpoint, as! have just stressed,
the pathogenesis of this imbalance could reflect overproduction
of lactic acid, underutilization, or both.
Overproduction of lactic acid is clearly recognized as the
mechanism of transient lactic acidosis in subjects undergoing
vigorous exercise and in those who have generalized convul-
sions [3, 4, 7, 65]. Similarly, for reasons I already have noted,
hypoxia constitutes a potent stimulus for lactic acid production.
However, given the extensive reserve capacity for lactate
)
Gluconeogenesis Lactate
Liver, renal cortex
Skin, erythrocytes, brain,/ skeletal muscle, intestinal mucosa
leukocytes, platelets, renal medulla, tissues of the eye
Anaerobic glycolysisGlucose Lactate
Fig. 3. The Con cycle.
renal cortex and is either reconverted to glucose or becomes
fuel for oxidation to CO2 and water. The cyclical relationship
between glucose and lactate, embodied in the Cori cycle (Fig.
3), ensures a continuous supply of glucose to tissues requiring
this substrate as fuel, such as brain and erythrocytes.
Another important dividend to the body's economy from the
unperturbed function of the Cori cycle is that the cycle provides
for the recapturing of hydrogen ions released into the body
fluids during glycolysis and thus allows for acid-base balance to
be maintained. What follows is a short overview of the acid-
base consequences of lactate metabolism.
Exogenously administered lactic acid is virtually completely
dissociated in body fluids, because its pK' is 3.86. However,
lactic acid as such is not produced at any step in the glycolytic
process; rather lactate, its conjugate base, is the actual end-
product of anaerobic glycolysis. Nonetheless the glycolytic
process also results in the release of protons in numbers
equivalent to the lactate produced, and the net effect is as if
lactic acid were released into the body fluids.
Conversion of glucose to lactate is coupled to the synthesis of
two molecules of ATP. The most simplified description of the
stoichiometry of this conversion is as follows (Equation 3):
C6111206 + 2ADP3 + 2Pi2 — 2CH3CH(OH)C00 + 2ATr + 2H20
(gtucose) (lactate)
Under steady-state conditions, the ratio of AlP to ADP re-
mains unchanged; consequently, all ATP synthesized in Equa-
tion 3 is promptly consumed (Equation 4):
2ATP + 21120 —* 2ADP3 + 2Pi2 + 2W
Summing up Equations 3 and 4 we obtain Equation 5:
C6H1206 —* 2CH3CH(OH)COO + 2W
(glucose) (lactate)
Thus, protons are released via the hydrolysis of ATP generated
during anaerobic glycolysis and not via dissociation of the
lactic acid species [97—99]. Protons freed from this process are
titrated by bicarbonate and nonbicarbonate buffers residing in
the intracellular and extracellular compartments. For acid-
base balance to be maintained, however, the protons released
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extraction in normal individuals, as evidenced by observations
during lactate infusion or transient overproduction by exercis-
ing muscle, it has become increasingly apparent that defective
utilization must be involved in the pathogenesis of most types of
persistent lactic acidosis. Observations in patients in circula-
tory shock have revealed substantial negative arteriovenous
differences for lactate across muscle, liver, and kidney; these
findings attest to a failure of the hepatic and renal mechanisms
for lactate removal [100]. Indeed, in view of the fact that both
pathways of lactate utilization depend critically on intact mito-
chondrial function, it is not surprising that tissue hypoxia
produces defective lactate processing (Fig. 2). Furthermore, the
evidence in support of the contention that nonhypoxic forms of
lactic acidosis are secondary to lactate overproduction [2] is
extremely weak [6, 7, 64]. In addition, observations from
experimental models of hypoxic [45, 101, 102] and nonhypoxic
[103] forms of lactic acidosis have clearly implicated both
overproduction and underutilization of lactate in the pathogene-
sis of the disorder. Thus, although we are far from being able to
quantitatively apportion the lactate load into overproduction
and underutilization columns, it appears likely that both limbs
of lactate metabolism might be defective in most forms of
clinical lactic acidosis. Accordingly, I should like to address
briefly some factors that are known to affect lactate utilization
by the liver and kidney. This knowledge has been derived from
experimental studies and its clinical relevance remains uncer-
tain; nonetheless, it allows for the formulation of an insightful
perspective of the pathogenesis of the disorder.
As I already have noted, hyperlactatemia produced by exoge-
nous infusion elicits increased utilization of lactate by the liver
and kidney [15, 20, 62, 72, 871. On the other hand, graded
hypoxia of the hepatic parenchyma leads to a progressive
diminution in hepatic lactate uptake; this reduction converts the
liver from a lactate-consuming to a lactate-producing organ [45,
71, 104, 105]. Thus, in early studies in the isolated perfused rat
liver, a reduction in hepatic blood flow by 40% to 67% resulted
in conversion from lactate uptake to lactate production [45,
105]. By contrast, in a more recent study of the same experi-
mental preparation [1061, lactate uptake was reduced only
modestly when hepatic blood flow was decreased by 67% of
normal; this finding of course reflects an increase in the hepatic
extraction ratio of lactate as hepatic blood flow decreases. At
more advanced degrees of hypoperfusion, however, severe
reductions in uptake were noted. Yet, even when blood flow
was reduced by 93%, minimal lactate uptake, but not output,
was still observed. At that point, liver intracellular pH averaged
7.03 as compared to a mean value of 7.25 during basal flow
[106]. Similarly, in-vivo studies in the dog have suggested a
large hepatic functional reserve for lactate disposal even during
severe ischemia [20]. At plasma lactate concentrations up to 4.2
mEq/liter, reductions in total hepatic blood flow by 70% or less
did not elicit a significant decrease in hepatic uptake. However,
further hypoperfusion markedly depressed lactate uptake and
even caused net lactate production [104]. The weight of the
evidence thus suggests that a reduction in hepatic blood flow to
less than 30% of normal cannot be compensated for and results
in decreased lactate utilization. Indeed, less severe degrees of
hypoperfusion might lead to substantial impairment of lactate
uptake if accompanied by greater degrees of hyperlactatemia.
Additional in vivo studies in the dog have shown that reduction
—2
Fig. 4. Relationship between extracellular pH (PHe) and lactate uptake
in the isolated perfused rat liver during simulated metabolic acidosis
(reprinted by permission from Clinical Science and Molecular Medi-
cine, vol 45, pp 543—549, copyright © 1973, The Biochemical Society,
London).
in oxygen tension to a mean Pa02 of 47 mm Hg decreased
hepatic lactate uptake by an average of —5.3 tEq/kgImin (mean
control value of 1.7 Eq/kgImin); this change indicated a
conversion to net lactate production. When more severe hypox-
emia was established (mean Pa02 of 35 mm Hg), net lactate
production by the liver was increased (mean of —9.2 Eq/kgI
mm) [1041. In addition to hypoxia, reduction of the hepatic
redox state induced by other means (for example, biguanides,
fructose, alcohol) has been shown to lead to impaired lactate
removal.
In studies of graded hemorrhage in the dog, renal lactate
uptake remained stable up to a blood loss of 30% of the basal
volume. Following a 40% blood loss, which resulted in a mean
arterial blood pressure of 72 mm Hg and a reduction in renal
blood flow by 66% of the prehemorrhage value, renal lactate
uptake decreased sharply; lactate production occurred during
hemorrhagic shock from a 45% to 50% blood loss at a mean
arterial blood pressure of 38 mm Hg and a 94% reduction in
renal blood flow [107, 108]. Following reinfusion of shed blood,
renal lactate uptake remained below baseline levels, probably
reflecting hypoxic tissue damage.
Moreover, strong evidence indicates that either severe meta-
bolic or respiratory acidosis impairs hepatic lactate uptake [15,
64, 70, 82—84, 109, 1101. Lactate uptake by the isolated perfused
rat liver decreased progressively at a perfusate pH of less than
7.10; indeed, when the perfusate pH was lowered below 7.0,
and liver intracellular pH fell to below 7.05, lactate output,
rather than uptake, occurred (Figs. 4 and 5) [70]. Additional
studies have revealed that gluconeogenesis from lactate is
markedly depressed in the isolated perfused rat liver when the
perfusate pH is lowered below 7.10 [83]. By contrast, in-vivo
and in-vitro studies have shown that moderate degrees of
acidosis do not significantly change hepatic lactate uptake [15,
62, 64, 70]. The suppressive effect of acidosis on lactate uptake
has been attributed to decreased gluconeogenesis from lactate
that occurs as a result of a fall in oxaloacetate concentration;
the latter could reflect inhibition of pyruvate carboxylase (PC)
enzymatic activity, increase in the [malate]/[oxaloacetate] ratio,
or both [84, 111]. It is interesting that myocardial lactate uptake
decreased by 30% in anesthetized dogs when blood pH was
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I
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lowered to 7.16 to 7.20 by the infusion of hydrochloric acid
[112].
Experiments in the isolated perfused rat liver have examined
the effects of combined hypoperfusion and acidosis on lactate
uptake and gluconeogenesis [85]. The conditions were selected
to simulate those prevailing during moderate to severe exercise
or during circulatory collapse; in addition, acidosis itself is
known to decrease hepatic blood flow [113]. Ischemia and
acidosis have separate inhibitory effects on hepatic lactate
uptake; thus, both could contribute to the defect in lactate
utilization characteristic of those settings [85]. Notably, epi-
nephrine exerted a marked ameliorating effect on lactate uptake
under these experimental conditions [86]. This observation
might have clinical relevance, in view of the high levels of
circulating epinephrine during acidemic states, such as strenu-
ous exercise and shock.
As expected from Equations 6 and 7, the metabolic process-
ing of lactate by gluconeogenesis or oxidation should increase
the hepatocyte pH by abstracting intracellular hydrogen ions;
by contrast, decreased lactate consumption should decrease
intracellular pH. This formulation assumes that at least part of
the lactate entering the hepatocyte is not accompanied by an
equivalent number of protons; support for this mechanism has
been obtained [6, 114]. Experiments in the isolated perfused
liver from several species indicate a direct relationship between
lactate consumption and a change in intracellular pH [106, 115,
116]. These interrelationships make it evident that the genera-
tion of severe acidemia during lactic acidosis carries in itself the
potential of initiating a vicious cycle in which the resultant
depressed hepatic intracellular pH would suppress lactate up-
take, thus leading to further aggravation of intracellular as well
as extracellular acidosis (Fig. 6). This ominous cycle would be
reinforced further by the depressive effects of acidosis on
hepatic blood flow [113].
A potent defense mechanism against a maladaptive positive-
feedback system such as this resides in the kidney. Evidence
from in-vitro and in-vivo studies suggests that acidosis substan-
tially increases renal lactate uptake and utilization via gluconeo-
genesis by stimulating the activity of the key gluconeogenic
enzyme PEPCK [11, 20, 76, 117]. This adaptation is apparent
within 2 to 4 hours from the onset of acidosis [118]. The
augmented renal contribution to lactate utilization during acido-
sis occurs despite the accompanying substantial decrease in
renal blood flow [113]. The mechanism underlying the opposite
effects of acidosis on lactate utilization by the liver and kidney
remains obscure. The overall impact of these responses on the
body's ability to handle a lactic acid load was quantified in rats
subjected to either bilateral nephrectomy or to a sham operation
and then made acidotic with NH4CI, Lactate removal was
slowed in nephrectomized animals by approximately 50% dur-
ing extracellular acidemia at pH 6,75; this result reflected both
the suppressed hepatic uptake and the absence of the renal
contribution. It was estimated that whereas the contribution of
the kidney to lactate removal was 16% at pH 7.45, it rose to 44%
at pH 6.75. Consequently, the enhanced ability of the kidney to
remove lactate during acidemia was sufficient to compensate
for approximately one-half of the concomitant fall in the extra-
renal (primarily hepatic) capacity for lactate extraction; the net
result was a relatively slight decrease in whole-body lactate
removal in the sham-operated animals [20]. It thus appears that
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Fig. 5. Relationship between intracellular pH (pI-fj) and lactate uptake
in the isolated perfused rat liver during simulated metabolic acidosis
(reprinted by permission from Clinical Science and Molecular Medi-
cine, vol 45, pp 543—549, copyright © 1973, The Biochemical Society,
London).
Fig. 6. Theoretical positive-feedback mechanism operating to decrease
systemic pH under conditions of severe lactic acidosis.
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Table 2. Synopsis of acid-base effects on lactate metabolisma
Acidosis Alkalosis
Lactate synthesis I t
(Glycolysis)
Lactate utilization
(Gluconeogenesis)
Liver I
Kidney
Net lactate production in vivo
t t
a Adapted from Ref. 12.
the role of the kidney as a lactate-consuming organ becomes
progressively more important as extracellular pH falls; in
severe acidemia, liver and muscle fall very short of compensat-
ing for the absence of kidneys.
The role, if any, of this renal adaptation in the pathogenesis of
the many forms of clinical lactic acidosis remains undefined.
However, it is intriguing to note that renal dysfunction is often
present in patients who develop either hypoxic or non-hypoxic
types of lactic acidosis as well as in those with phenformin-
induced lactic acidosis [3—7, 65, 77, 119]. Phenformin has been
shown to inhibit renal gluconeogenesis both in vivo and in vitro,
in addition to its suppressive effect on hepatic gluconeogenesis
[4, 120, 1211.
Table 2 presents a synopsis of the currently known effects of
changes in systemic pH on lactate metabolism. Acidosis inhib-
its lactate synthesis, retards hepatic lactate uptake, but pro-
motes renal lactate extraction and utilization. On the other
hand, alkalosis stimulates lactate generation; no consistent
effect of alkalosis on lactate utilization has been identified. As I
have noted, experimental observations under basal conditions
as well as during stimulated lactate production (exercise, hy-
poxemia, phenformin administration) reveal suppression of net
lactate production in vivo by acidosis and augmentation by
alkalosis. Nonetheless, additional research is required to define
the aggregated effect of the multitude of influences of acidosis
on lactate metabolism. The level of severity of the acidosis, its
often rapidly evolving course, and the associated—primary and!
or secondary—hemodynamic disturbances are among the fac-
tors that add special complexity to this task. It is possible, for
example, that during severe acidosis the aggregate effect of
these various influences might lead to a pH-induced increase in
net lactate production because of the overriding importance of
impaired hepatic lactate utilization.
Clinical features
The clinical presentation of lactic acidosis is extremely
variable and heavily influenced by the manifestations of the
underlying disease. Nonetheless, its development is often her-
alded by the sudden onset of malaise, weakness, anorexia,
vomiting, and a deterioration in mental status. Hyperventila-
tion, tachycardia, hypotension, and circulatory instability are
common associated findings [3, 4, 65]. The diagnosis of lactic
acidosis frequently is strongly suspected on clinical grounds
and is supported by the finding of an otherwise unaccounted-for
elevation in the concentration of plasma undetermined anions
(anion gap), often in the company of hypobicarbonatemia and
acidemia. Of course, confirmation of the diagnosis rests with
the finding of an elevated plasma lactate level. The clinical
significance of lactate levels in the range of 2 to 4 mEq/liter
remains unclear. On the other hand, lactate levels of 5 mEq!liter
or greater usually point to the seriousness of the clinical
condition: the higher the level, the greater the gravity of the
patient's status and the worse the prognosis [122]. I would like
to discuss some general aspects of the clinical presentation of
lactic acidosis.
Acid-base
Although substantial hypobicarbonatemia is a regular accom-
paniment of lactic acidosis, this need not be the case. If lactic
acidosis is superimposed on a preexisting hyperbicarbonatemic
state, the accumulated lactic acid may not be sufficient to drive
the plasma bicarbonate to frankly subnormal levels. The only
laboratory clue to the coexistence of lactic acidosis in this
setting is the inappropriately elevated plasma anion gap.
It generally has been assumed that in uncomplicated lactic
acidosis (and, in fact, in all types of organic acidosis) reciprocal
stoichiometry is maintained between the decrement in plasma
bicarbonate and the increment in anion gap. This assumption
originates from the expectation that titration precisely replaces
bicarbonate with the anion of the offending acid, that is, lactate.
Consequently, plasma chloride concentration, unaffected by
titration, is assumed to remain normal. As a corollary, when
lactic acidosis is found to be associated with hypochloremia
(that is, when the increment in anion gap is greater than the
decrement in bicarbonate from normal), it has been argued that
an antecedent metabolic alkalosis might have been present but
presumably is now hidden by the overriding impact of the
acidosis. Undoubtedly, in the untreated patient, close corre-
spondence often exists between the decrement in plasma bicar-
bonate and the increment in anion gap, as well as the rise in
plasma lactate. Yet on several occasions we have been puzzled
by the occurrence of moderate hypochloremia (in the absence
of corresponding hyponatremia) in patients with lactic acidosis
but without an identifiable cause for the putative underlying
alkalosis. Recent experiments in our laboratory have suggested
that some degree of hypochloremia might be an integral part of
the prevailing acidosis [1231. A stable degree of lactic acidosis
was produced in nephrectomized rats by infusing the racemic
mixture of L(+)- and D(—)-lactic acid over a 3-hour period. As
Figure 7 illustrates, a decrement in plasma chloride concentra-
tion accounted, on average, for 38% and 48% of the increment
in plasma anion gap at 1 and 3 hours, respectively. We
theorized that this acidosis-induced hypochloremia was due to
expansion of the extracellular compartment secondary to the
extrusion of cellular cations that occurs in the process of
buffering [123]. Although this mechanism provides a plausible
explanation for the puzzling hypochloremia I already have
referred to, its relevance to the clinical setting remains to be
determined. Assuming that this mechanism is operative, one
might not expect the generation of acidosis-induced hypochlo-
remia at the very onset of acidosis before substantial ionic shifts
have occurred; this prediction is supported by studies of
hyperacute, transient lactic acidosis secondary to a single
grand-mal seizure in which hypochloremia was not present [691
and by observations in humans following maximal exercise of
short duration [60]. By contrast, acidosis of several hours
duration might feature this abnormality unless offsetting factors
were involved [123].
acidosis, and its spontaneous recovery is not accompanied by a
significant change in plasma potassium [69]. Although hyperka-
lemia occurs commonly in patients with various types of lactic
acidosis, the level of plasma potassium correlates poorly with
the degree of acidemia; moreover, most of the hyperkalemic
patients are hypercatabolic, have renal dysfunction, or both
[136]. It is doubtful whether organic acidemia in general is a
cause of hyperkalemia at all [136]. Despite various hypotheses,
the reasons for the disparate response of plasma potassium to
lactic acidosis as compared to mineral acidosis remain unknown
[132, 133].
Miscellaneous laboratory findings
Serum phosphate concentration is usually increased in pa-
tients with lactic acidosis [130, 137, 138]. The pathogenesis of
this abnormality is unclear but in all probability reflects a
release of inorganic phosphate from cells [139],
Hyperurieemia, another regular feature of lactic acidosis,
results from decreased renal excretion of urate owing to com-
petitive inhibition of tubule urate secretion by the lactate ion
[140].
Finally, the plasma levels of certain amino acids are frequent-
ly increased in patients with lactic acidosis; the most notable
increase corresponds to alanine, but proline, valine, lysine, and
leucine are also increased substantially [141].
Causes of lactic acidosis
The causes of acquired lactic acidosis are catalogued in Table
3. Increased oxygen demand arises from intense voluntary
exercise, which is certainly the most common cause of transient
lactic acidosis. Substantial hyperlactatemia also occurs in gen-
eralized convulsions, the clinical equivalent of strenuous volun-
tary exercise. Tissue hypoxia is by far the most common cause
of clinically significant lactic acidosis. The decrease in oxygen
availability in the tissues results from reduced tissue perfusion,
reduced arterial oxygen content, or both. On the other hand, a
number of drugs and toxic substances can cause lactic acidosis
in the absence of tissue hypoxia. Certain clinical disorders
including diabetes mellitus, liver failure, sepsis, and neoplastic
diseases predispose the patient to lactic acidosis. Detailed
descriptions of the causes of lactic acidosis can be found
elsewhere [3—7, 65, 135, 142]. Congenital lactic acidosis results
from a variety of relatively rare, congenital enzymatic defects
that affect the metabolism of pyruvate and lactate (Table 4).
Treatment
Management of lactic acidosis must be directed at prompt
identification and aggressive treatment of the underlying cause
or predisposing disorder whenever possible. Although judicious
administration of alkali might be warranted to ameliorate the
prevailing acidemia and thus possibly prevent catastrophic
cardiovascular sequelae, such maneuvers should only be re-
garded as temporizing and adjunctive to cause-specific mea-
sures. Critical tissue hypoxia is the underlying culprit in most
cases of clinical lactic acidosis; therapeutic measures therefore
should be directed at augmenting oxygen delivery to the tissues.
Indeed, focusing one's efforts on merely treating the acidemia
by alkali infusion can be likened to treating diabetic ketoacido-
sis with bicarbonate while neglecting insulin administration.
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Fig. 7. Contribution of hypochloremia to the increment in plasma anion
gap during lactic acidosis produced by infusion of the racemic mix-
ture of L(+)- and D(—)-lactic acid in the nephrectomized rat (from Ref.
123).
The degree of acidemia generated by a given level of lactic
acidosis-induced hypobicarbonatemia is, of course, determined
by the attendant level of PaCO2. No systematic observations on
the magnitude of the ventilatory adaptation to lactic acidosis are
available. Retrospective studies have variably reported that this
response is greater than, equal to, or less than that associated
with other types of metabolic acidosis [3, 124—127]. In an animal
model of lactic acidosis, the degree of ventilatory adaptation
was virtually identical to that observed in mineral acid-induced
metabolic acidosis [123]. Stimulation of carotid and aortic
chemoreceptor activities in response to lactic acid-induced
metabolic acidosis has been shown in the cat [128]. Although
hypocapnia regularly occurs in clinical lactic acidosis [129], it
often is difficult to ascribe it entirely to the adaptive response in
view of the frequent coexistence of other processes known to
stimulate alveolar ventilation, for example, hypoxemia, hypo-
tension, sepsis, pulmonary disease, and hepatic failure. On the
other hand, processes that lead to ventilatory failure can limit
the ventilatory response to lactic acidosis or superimpose frank
hypercapnia; of course, acidemia is compounded under such
circumstances.
Plasma potassium concentration
In contrast to mineral acid-induced acidosis, lactic acidosis of
comparable severity induced by exogenous infusion of lactic
acid is not associated with a significant change in plasma
potassium concentration [130—135]. Similarly, hyperkalemia is
not observed in patients with grand mal seizure-induced lactic
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Table 3. Causes of acquired lactic acidosisa
Increased oxygen demand
1. Vigorous voluntary exercise
2. Generalized convulsions
Reduced oxygen availability (tissue hypoxia)
1. Reduced tissue perfusion
a. Shock or incipient shock
b. Acute left ventricular failure
c. Low cardiac output
2. Reduced arterial 02 content
a. Asphyxia
b. Hypoxemia (Pa02 <35 mm Hg)
c. Carbon monoxide poisoning
d. Very severe anemia
Drugs and toxins
1. Ethanol
2. Biguanides (phenformin, metformin, buformin)
3. Various intoxications (e.g., methanol, ethylene glycol,
salicylates, isoniazid, streptozotocin, cyanide, nitroprusside,
papaverine, paracetamol, nalidixic acid)
4. Fructose, sorbitol, and xylitol
5. Epinephrine, norepinephrine
Certain disorders
1. Diabetes mellitus
2. Liver failure
3. Sepsis
4. Neoplastic diseases
5. Renal failure
6. Iron deficiency
7. Short-bowel syndrome [D(—)-lactic acidosis}
Idiopathic (spontaneous) lactic acidosis
Adapted from Refs. 3, 4, and 65.
Table 4. Causes of congenital lactic acidosisa
Defects in gluconeogenesis
I. Glucose-6-phosphatase deficiency (type I glycogen storage
disease—von Gierke's disease)
2. Fructose-bisphosphatase deficiency
3. Pyruvate carboxylase deficiency
Defects in pyruvate oxidation
1. Pyruvate dehydrogenase deficiency
2. Oxidative phosphorylation defects
a Adapted from Refs. 4 and 65.
General measures
Swift steps should be taken to evaluate and treat cardiovascu-
lar collapse, low-cardiac-output states, hypoxemia, and sepsis.
As a general rule, aggressive hemodynamic monitoring in an
intensive care setting should be employed in directing therapeu-
tic measures. Hypovolemia requires prompt extracellular fluid
volume repletion. Every effort should be made to limit the use
of vasoconstrictor agents in treating low-cardiac-output states;
such agents aggravate the ischemia of peripheral tissues, wors-
en the severity of lactic acidosis and, in turn, prove counterpro-
ductive for the patient's hemodynamic status [3, 4, 65, 1431.
Rather, administration of inotropic compounds along with
afterload reducing agents should be used. Extreme vigilance
should be exercised for the early detection of fatigue of the
ventilatory apparatus and the presence of critical hypoxemia
and/or hypercapnia; if necessary, artificial ventilation should be
implemented promptly [144]. The outcome of lactic acidosis
depends on the severity and reversibility of the underlying
condition. If the cause cannot be corrected, lactic acidosis is
virtually certain to advance, and the overall prognosis is grim.
By contrast, successful treatment of the underlying condition
leads to prompt improvement of the systemic acid-base status
as the metabolism of the accumulated lactate generates an
equivalent amount of endogenous bicarbonate. Typically, the
mild to moderate degrees of lactic acidosis accompanying
uncomplicated acute alcoholism, acute pulmonary edema, self-
limited grand-mal seizures, and diabetic ketoacidosis abate with
cause-specific and general supportive measures without the
need for treatment of the acidosis itself.
Alkali therapy
Cause-specific measures should be complemented by alkali
therapy whenever the prevailing acidemia is severe, that is,
when the pH falls below approximately 7.20 [3, 4, 6, 65, 145]. In
the absence of a complicating element of respiratory acidosis
(which, if present, warrants prompt efforts at increasing alveo-
lar ventilation), such degrees of acidemia usually imply decre-
ments in plasma bicarbonate concentration below 10 mEq/liter.
Intravenous sodium bicarbonate should be administered to
raise the plasma bicarbonate concentration to 10 to 12 mEq/liter
and to maintain blood pH at or above 7.20. This recommenda-
tion is based on strong evidence indicating that severe acide-
mia—that is, pH below 7.20—exerts adverse hemodynamic
effects, including impairment of cardiac contractility; reduction
of cardiac output, arteriolar dilation, dangerous degrees of
hypotension, and diminution in hepatic and renal blood flow;
peripheral venoconstriction leading to central redistribution of
blood volume, thereby augmenting the workload of a depressed
myocardium; increased pulmonary vascular resistance leading
to "shock lung"; and bradycardia and sensitization to various
malignant ventricular arrhythmias [75, 113, 145—148]. Although
acidemia stimulates the release of catecholamines, it also
progressively attenuates the inotropic and chronotropic effects
of these sympathetic mediators on the heart; thus, at pH values
below 7.20, the direct negative inotropic effect of acidemia
becomes dominant. A recent study, which revealed rapid
desensitization and uncoupling of human /3-adrenergic recep-
tors in an in-vitro model of lactic acidosis, provides a plausible
explanation for the characteristic lack of responsiveness to
sympathetic mediators [149]. These observations, which sug-
gest that pretreatment with /3-adrenergic blocking agents sensi-
tizes the myocardium to the adverse hemodynamic effects of
acidemia, might have clinical relevance. It therefore should be
evident that alkali therapy must be administered (1) to possibly
avoid the superimposition of severe acidemia-related hemody-
namic compromise on that already caused by the underlying
disease; and (2) to reinstate cardiac reactivity to endogenous as
well as exogenous catecholamines until the underlying condi-
tion can be identified and treated. Beyond its direct beneficial
effects, such treatment provides a certain measure of safety
against the superimposition of additional acidifying stresses; at
values below 10 mEq/liter, a further small decline in plasma
bicarbonate concentration and/or a small increment in PaCO2
can cause catastrophic acidemia.
The utility of this time-honored, adjunctive measure in treat-
ing lactic acidosis has been criticized strongly in recent years [7,
No treatment NaCI NaHCO3
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47, 49—5 1, 142]. Critics have argued that despite the established
practice of vigorously treating severe lactic acidosis with sodi-
um bicarbonate, mortality rates continue to be overwhelming.
This is hardly a persuasive criticism in itself, since the underly-
ing clinical entities—and root causes of the tactic acidosis—
often are of grave severity. Alkali administration, although
designed to potentially limit the gravity of the metabolic distur-
bances and their hemodynamic epiphenomena, is not expected
to alter materially the course of the background disorder. As I
already have emphasized, alkali is used as symptomatic treat-
ment directed at severe, life-threatening acidemia; unless spe-
cific measures prove successful in relieving critical tissue
hypoperfusion and hypoxia, the outcome is certain to be
dismal.
Notwithstanding, an even more serious indictment of bicar-
bonate therapy has been handed down recently. Its critics
charge that such therapy, far from being beneficial, actually
exerts a detrimental effect on the course of lactic acidosis [7, 47,
49—51, 142]. I should like to review the chief pieces of experi-
mental evidence supporting this charge.
Hypoxic lactic acidosis was induced in anesthetized dogs
with fixed ventilation at an Fi02 of 8%, with resulting Pa02
values of 25 to 30 mm Hg [51]. The impact of three treatment
options—no therapy, administration of 1 M NaCl at 2.5 mmol/
kg/hr, or an equivalent amount of 1 M NaHCO3—applied for 60
minutes was studied with regard to blood acid-base status,
lactate metabolism, and systemic hemodynamics. As Figure 8
shows (left panel), animals in all three treatment groups experi-
enced significant and similar decrements in pH and in plasma
bicarbonate concentration during the experimental period.
Moreover, although plasma lactate rose further in all groups
after one hour of observation, the plasma lactate level was
significantly higher in the NaHCO3 group as compared to the
remaining two groups. Skeletal muscle lactate production did
not change significantly in any of the three groups. Gut lactate
production remained unchanged in the groups receiving either
no treatment or NaHCO3, but it decreased significantly in the
NaC1 group (Fig. 8, middle panel). Hepatic lactate extraction
remained unchanged in all three groups. The baseline mean
aortic pressure and blood flow to the gut and liver were normal
in all groups, whereas the cardiac index was 130% higher than
that in the control animals. No significant changes in blood
pressure and cardiac index were noted in the NaC1 group during
the course of treatment; by contrast, both these parameters fell
in the animals receiving either no treatment or NaHCO3, more
so in the latter group (Fig. 8, right panel). Observations on the
fate of blood flow to the gut and liver were not provided.
Although interesting, the relevance of these observations to
clinical hypoxic lactic acidosis remains unclear. After all, the
clinical entity is usually characterized by a decreased, not
increased, cardiac output, and by decreased, rather than nor-
mal, blood pressure and organ perfusion. In addition, the
pathogenesis of the augmentation in the plasma lactate level
during NaHCO3 treatment is somewhat puzzling when viewed
in the context of the remaining evidence. Thus, the observed
hemodynamic deterioration in the NaHCO3 group apparently
was insufficient to alter either lactate production by gut and
skeletal muscle (the main sources of lactate in this model) or
hepatic lactate extraction; nonetheless, an exaggerated aggra-
vation of hyperlactatemia was noted. The investigators ob-
served that although systemic acid-base status did not change
during the course of the experiment, portal PCO2 averaged 55
mm Hg after NaHCO3 treatment—a value significantly higher
than the 45 mm Hg after NaC1 treatment, It is unclear to what
extent the fixed ventilation of the animals affected this result.
Assuming that the basal values of this parameter did not differ
between the NaCI- and NaHCO3-treated groups, it is possible
that this degree of portal hypercapnia might have produced
excessive intrahepatic acidification, thus adversely affecting
hepatic lactate uptake [70]. Yet extraction of lactate by liver
remained unaltered by treatment in all groups. Furthermore,
the disparate hemodynamic response between the NaCI- and
NaHCO3-treated groups of animals,despite the similarity in the
amount of sodium and volume administered and the prevailing
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acid-base status, is intriguing but puzzling. No mortality was
reported in any of the studied groups [511.
Using a different experimental model, the same group of
investigators has produced evidence supporting their thesis of
an adverse role of bicarbonate therapy in lactic acidosis [49].
Lactic acidosis was induced in diabetic dogs (having undergone
surgical pancreatectomy) via infusion of intravenous phenfor-
mm. Following 90 minutes of treatment with either NaHCO3 (1
mmollmin as a 1 M solution) or equivalent amounts of NaCl,
systemic acid-base status remained unchanged in both groups;
however, plasma lactate remained essentially unaltered in the
NaCI-treated group but increased twofold in the NaHCO3-
treated animals. Lactate production by the gut doubled in the
NaHCO3 group and remained unchanged in the NaC1 group;
hepatic lactate uptake was unaffected by either treatment.
Moreover, cardiac output, hepatic portal venous blood flow,
and liver and erythrocyte intracellular pH all decreased in the
NaHCO3-treated animals but remained essentially unchanged
in the animals given NaCl. However, muscle intracellular pH
fell significantly in the NaCl, but not in the NaHCO3, animals.
After 4 hours of observation, the same mortality rate, 83%, was
seen in both groups.
Again, the relevance of these experimental observations to
the clinical disorder is uncertain. Intravenous phenformin in
high doses is cardiotoxic and produces consistent decreases in
cardiac output and systemic hemodynamics even before any
changes in systemic acid-base status are detectable [96, 103].
Why NaHCO3 administration would increase phenformin's
cardiotoxicity as compared to equimolar amounts of NaC1
remains unclear. It has been suggested that because phenformin
is a strong base, alkalinization would intensify its diffusion
across plasma membranes to intracellular binding sites [150].
Despite some inconsistencies, the evidence derived from
these [49, 51] and other studies supporting the notion that
bicarbonate administration or, in general, alkalinization (rela-
tive or absolute) of body fluids stimulates lactate production is
strong. Even massive doses of alkali may not succeed in
substantially increasing the plasma bicarbonate level in malig-
nancy-associated chronic lactic acidosis; indeed, a direct stoi-
chiometric relationship between alkali administration and acid
production, presumably by the malignancy, has been demon-
strated [43, 44]. Moreover, there is a dynamic inverse relation-
ship between the prevailing acidity of body fluids and either
ketoacid production during ketoacidosis [12, 53, 54] or lactate
production during hypoxemia-induced lactic acidosis [42]. A
central difference between clinical hypoxic lactic acidosis and
the hypoxemia-induced experimental counterpart is that the
latter is a model of relatively controlled lactic acidosis in which
the tendency toward continued lactate production apparently is
compensated for by salutary hemodynamic adjustments as well
as by the negative feedback exerted by the prevailing acidemia.
By contrast, clinical hypoxic lactic acidosis is often a precipi-
tous, explosive state in which the prevailing hemodynamic
disarray gives rise to rapidly advancing lactic acidosis that, in
turn, aggravates the circulatory compromise, diminishes hepat-
ic and renal blood flow, and leads to more severe acidemia by
accelerating production and decreasing uptake of lactate. It is
thus clear that the negative feedback control system between
systemic pH and organic acid production (suggested by experi-
mental studies) is overriden during clinical hypoxic lactic
acidosis, and that it gives way to an all-too-familiar lethal
vicious cycle. Consequently, I reject any extrapolations of the
existing experimental findings to the clinical setting, and I
dispute the implication that the clinical use of bicarbonate
should be abandoned. Nonetheless, the cumulative experimen-
tal evidence has reinforced the clinical dictum that bicarbonate
should be administered wisely and cautiously.
I believe strongly, therefore, that judicious administration of
bicarbonate along the guidelines given here is imperative. By
returning systemic pH above the hemodynamically critical
level, the clinician "buys time" that might allow control of the
underlying causative illness. This relative alkalinization proba-
bly tends to increase lactate production, but this tendency
should be offset by the improved state of tissue perfusion and,
possibly, by the augmentation of hepatic lactate extraction. For
this reason the clinician should take pains to use the smallest
possible amounts of bicarbonate that will allow the return of
systemic pH to hemodynamically safe levels [144].
No simple prescription exists for predetermining the amount
of bicarbonate necessary for achieving this goal in the individ-
ual patient. The only recourse available to the clinician is to
perform an individual titration for each patient. Frequent moni-
toring of the acid-base status during bicarbonate therapy is
essential for a cogent appraisal of additional bicarbonate re-
quirements. That the goal of raising plasma bicarbonate by
administering alkali can be achieved is well documented in
many forms of clinical lactic acidosis, but widely variable rates
of bicarbonate administration are required [3, 65]. This variabil-
ity in dose requirement largely reflects the fact that the rate of
lactic acid production is itself extremely variable. The clinician
also should note that the apparent space of distribution for
bicarbonate is enlarged in hypobicarbonatemic states [151];
thus, calculating bicarbonate doses on the basis of the normal
value of the apparent space of distribution for bicarbonate of
40% to 50% body weight will underestimate the bicarbonate
requirements. Indeed, when lactic acid production proceeds
extremely rapidly, administered bicarbonate can fail to effect
detectable changes in plasma bicarbonate concentration, the
apparent space of distribution for bicarbonate becoming essen-
tially infinite.
Administration of large and occasionally massive amounts of
bicarbonate entails certain risks [3, 4, 65, 144]. Hypernatremia
and marked hyperosmolality, and volume overload are common
problems. Establishment of adequate diuresis with potent loop
diuretics allows the infusion of large doses of alkali without
superimposing iatrogenic circulatory compromise. On the other
hand, if renal failure is present, peritoneal dialysis, hemodialy-
sis, or hemofiltration may be required [152—154]. "Overshoot"
alkalosis is an extremely undesirable complication of aggressive
alkali dosing and underscores the strong recommendation for
judicious bicarbonate administration; the swift transition from
severe acidemia to alkalemia can produce tetany, altered men-
tal status, generalized convulsions, and cardiac arrhythmias.
These complications arise from two mechanisms. The first is
the persistence of hyperventilation at levels inappropriate for
the newly prevailing plasma bicarbonate concentration—either
because of the known delay of medullary chemoreceptors to
register the amelioration of acidity in the systemic circulation,
or because of pH-independent stimuli of alveolar ventilation.
Second, substantial elevations in plasma bicarbonate, occasion-
766 Nephrology Forum
ally to frankly supranormal levels, can result from the compos-
ite effect of inordinately large exogenous alkali loads and from
the regeneration of endogenous alkali from the metabolism of
the accumulated lactate [3, 4, 65, 144]. Special attention should
be paid to the level of plasma potassium to prevent hypokalemia
during treatment, especially in patients receiving digitalis. Ad-
ministration of bicarbonate produces increments in PaCO2 that
originate both from the release of CO2 during the internal
titration of bicarbonate and from pH-mediated suppression of
alveolar ventilation [151, 155]. In patients with adequate gas
exchange, this small effect is usually inconsequential, but it can
be clinically important in patients with borderline oxygenation.
Bicarbonate administration during resuscitative efforts in pa-
tients with cardiorespiratory arrest prior to the reestablishment
of gas exchange may compound the often severe acidemia. This
effect occurs due to complete retention of the CO2 released
during the rapid titration of infused bicarbonate by the ongoing
lactic acid production [1561. Finally, concerns that the changes
in pH induced by judicious alkali administration will produce a
clinically significant decrease in tissue oxygen delivery by
enhancing hemoglobin's affinity for oxygen (Bohr effect) are
unfounded [144, 157].
Additional measures
Insulin administration has been suggested as a therapeutic
measure in diabetic patients with lactic acidosis, whether or not
biguanide agents are involved [158, 159]. Theoretically, insulin
could exert a beneficial effect by stimulating the oxidation of
pyruvate through the pyruvate dehydrogenase (PDH) pathway
and by limiting the flow of gluconeogenic amino acids to the
liver. Although the evidence supporting this therapy is tenuous,
it is probably advisable to include insulin in the treatment plan
in this setting [4, 7, 160].
In a single patient with lactic acidosis in association with
congestive heart failure, normal cardiac output, and normoten-
sion but clinical evidence of severe peripheral vasoconstriction,
afterload reduction with sodium nitroprusside led to striking
resolution of the metabolic abnormality [161]. No additional
experience has been documented in such a setting, however,
and the efficacy of this modality thus remains unproven. As I
already have mentioned, afterload reducing agents should be
used in preference to vasoconstrictors in the treatment of low-
cardiac-output states [162, 1631.
Methylene blue, an oxidizing agent, was proposed as treat-
ment for lactic acidosis on the premise that it promotes the
conversion of NADH to NADt and thus restores the cellular
redox state; however, clinical application of this therapy has
not proved successful [164].
Thiamine and lipoic acids, agents that act as coenzymes for
the PDH enzyme complex, have been utilized occasionally in
the treatment of patients with lactic acidosis, but experience is
limited and therefore their utility remains uncertain [3, 4, 165].
However, thiamine represents remarkably effective specific
therapy in patients with lactic acidosis in association with
fulminant beriberi [165, 166].
Peritoneal dialysis, hemodialysis, or hemofiltration is a useful
adjunctive measure in the management of patients with im-
paired renal function who require large alkali loads [152—154,
167, 1681. In addition to preventing or treating the associated
volume overload, dialysis conveniently and reliably provides
the needed alkali. Obviously, in view of impaired lactate
utilization there is no sense in employing lactate-buffered
dialysate. Acetate-buffered dialysate has been used effectively
but should be avoided in patients with hemodynamic insuffi-
ciency or instability and in those prone to acetate intolerance.
Bicarbonate-buffered peritoneal dialysis or hemodialysis has
been employed successfully in the management of patients with
lactic acidosis [153, 167, 168]. Its attractions include provision
of bicarbonate as such, rather than of alkali precursors; avoid-
ance of the risk of further hypobicarbonatemia due to an
imbalance between the diffusive losses of bicarbonate in the
dialysate and alkali generation from the acetate; the prevention
of acetate dialysis-induced hypoxemia; and probably a better
hemodynamic profile. Bicarbonate-buffered peritoneal dialysis
is particularly suitable in the management of patients with
circulatory failure. In addition, dialysis can remove drugs and
toxins such as methanol and salicylates; hemodialysis does not
remove appreciable quantities of phenformin, however [169].
Finally, dialysis can remove lactate from the body fluids and
thus often prevent rebound hyperbicarbonatemia. Recent evi-
dence suggests that hyperlactatemia per se (independent of
changes in systemic pH) exerts adverse effects on myocardial
contractility. In-vitro studies have shown that increased lactate
concentration impairs frog atrial muscle contractility [170],
leads to swelling and reduction in oxidative phosphorylation in
isolated beef heart mitochondria [171], and inhibits glucose
utilization by ischemic rat myocardium at the glyceraldehyde 3-
phosphate dehydrogenase step [172]. In addition, hyperlactate-
mia per se decreased exercise tolerance in normal rats [173]. By
contrast, increased lactate concentration did not decrease the
contractility of the papillary muscle of the cat [147]. If an
adverse hemodynamic effect of hyperlactatemia were con-
firmed, it would provide a plausible explanation for evidence of
hemodynamic deterioration following bicarbonate administra-
tion independent of changes in systemic pH [49, 51, 96]. Such
confirmation would support therapeutic strategies specifically
aimed at reducing plasma lactate.
Finally, dichloroacetate (DCA) is an exciting investigational
agent that holds promise as a therapeutic tool in lactic acidosis.
Because DCA stimulates PDH activity in many tissues, it
augments the oxidation of pyruvate to acetyl-CoA [174, 175].
This effect directs lactate, alanine, and pyruvate into the
formation of carbon dioxide, fatty acids, and ketone bodies
(Fig. 1) and consequently inhibits hepatic gluconeogenesis from
these 3-carbon precursors. Decreases in the plasma levels of
lactate, alanine, pyruvate, and glucose occur, whereas plasma
ketone-body concentration increases [176—179]. In nonacidotic
diabetic patients, DCA decreases lactate levels [180], and it can
improve the disordered lactate metabolism in experimental
lactic acidosis produced by functional hepatectomy, phenfor-
mm administration, exercise, epinephrine infusion, or hypoxe-
mia [52, 175, 177, 181—184]. In one study [52], administration of
DCA to diabetic dogs with phenformin-induced lactic acidosis
significantly lowered plasma lactate and significantly raised
plasma bicarbonate concentration and pH as compared to a
similarly prepared group of animals that received NaHCO3
treatment (Fig. 9). Moreover, whereas treatment with NaHCO3
could not arrest the progressive fall in the cardiac index,
treatment with DCA returned cardiac index to the control value
(Fig. 10); mortality during a 4-hour treatment period with either
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Fig. 9. Effect of dichloroacetate (DCA) or NaHCO3 treatment on blood
acid-base composition and lactate level during phenformin-induced
lactic acidosis in the diabetic dog (reproduced from The Journal of
Clinical Investigation, 1982, vol. 70, pp. 853—862 by copyright permis-
sion of The American Society for Clinical Investigation).
modality averaged 91% in dogs receiving NaHCO3, as com-
pared with 22% in dogs treated with DCA [52]. It is interesting
that treatment with DCA resulted in increased liver lactate
uptake in association with increased liver intracellular PH; thus,
the decreased hyperlactatemia noted could be the composite
effect of decreased lactate production due to improved cardiac
performance and increased lactate utilization. These authors
made similar observations about DCA treatment in dogs with
functional hepatectomy and lactic acidosis [52]. The decisively
better outcome of DCA therapy compared to NaHCO3 adminis-
tration in this study often has been quoted as a potent argument
against the utility of NaHCO3 therapy [7, 49, 51]. I find this
argument unconvincing, however. To attempt to draw a paral-
lel, I do not think it valid to conclude that NaHCO3 has no role
in the management of diabetic ketoacidosis on the basis of
improved outcome of patients treated with insulin as compared
to outcome in those treated with alkali alone.
Two studies have provided evidence in support of a beneficial
role of DCA in the treatment of hypoxemia-induced lactic
Time, hours
Fig. 10. Effect of dichioroacetate (DCA) or NaHCO3 treatment on
cardiac index during phenformin-induced lactic acidosis in the diabetic
dog (reproduced from The Journal of Clinical Investigation, 1982, vol.
70, pp. 853—862 by copyright permission of The American Society for
Clinical Investigation).
acidosis in rats and dogs [183, 184]. Unlike treatment with
sodium chloride, DCA administration resulted in attenuation of
the hyperlactatemia, hypobicarbonatemia, and acidemia in hyp-
oxemic rats; moreover, the animals receiving DCA maintained
higher mean blood pressures and greater rates of urine flow and
sodium excretion [183]. Similarly, administration of DCA to
hypoxemic dogs significantly increased plasma bicarbonate and
pH, and stabilized plasma lactate concentration; by contrast,
progression of hypobicarbonatemia, acidemia, and hyperlacta-
temia was noted in the group receiving sodium chloride. Addi-
tionally, animals given DCA, but not those given NaCl, experi-
enced increased hepatic lactate extraction, decreased liver and
muscle lactate levels, and elevated muscle intracellular pH
[184].
Some data on DCA are available in humans as well. Thirteen
gravely sick, hypotensive patients with lactic acidosis in associ-
ation with various predisposing illnesses (such as renal and
hepatic disease, sepsis, leukemia or lymphoma, arrhythmias)
were given DCA [185]. Of the 11 who did not receive concur-
rent treatment with bicarbonate, each of 7 experienced at least a
20% decrease in plasma lactate (Fig. 11); this subgroup had a
significant, mean reduction of lactate of 80% (from an average
value of 14.2 to 2.8 mEq/liter) and significant increases in
plasma bicarbonate and pH (from 14 to 21 mEq/liter and from
7.24 to 7.39, respectively). The fall in plasma lactate persisted
for several hours after treatment with DCA was terminated. In
10 of the 13 treated patients, increases in systolic blood
pressure of 10 to 40 mm Hg were noted soon after the initiation
of DCA treatment; in 4 patients whose cardiac output was
monitored, the increase in systolic blood pressure was accom-
panied by a significant mean increase in cardiac output of 21%
(from 6.2 to 8.4 liters/mm). These findings are in accord with
previous observations indicating that DCA improves cardiac
function in dogs with experimentally induced myocardial isch-
emia or lactic acidosis [52, 186]. Because the drug is known to
augment aerobic oxidative metabolism in cardiac tissue [187], it
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Fig. 11. Effect of dichloroacetate (DCA) treatment on plasma lactate
and plasma drug concentration in a patient with tactic acidosis in
association with hypotension, sepsis, hepatic disease, and severe
anemia [reprinted by permission of The New England Journal of
Medicine (vol 309, pp 390—396, 1983)1.
might improve myocardial contractility. These hemodynamic
effects might complement the metabolic action of DCA in
decreasing the plasma lactate level. Unfortunately, despite
these favorable metabolic and hemodynamic consequences, all
but one of the patients in that study died of their underlying
disease [185]. Additional human experience with DCA includes
observations in 8 adult patients with severe lactic acidosis in
association with biguanide therapy, hypotension, sepsis, or
malignancy; 3 of the 8 had a greater than 20% reduction in
plasma lactate levels, and 2 of the 3 survived [185, 188, 1891.
Moreover, of 7 children with congenital forms of lactic acidosis,
DCA produced biochemical and/or clinical improvement in 4
[190—194]. In general, no appreciable drug toxicity has been
observed in studies of short-term administration of DCA [180,
185, 188, 189, 190—193, 1951. By contrast, serious side effects
have been noted with long-term administration, including limb
paralysis, cataracts, increased urinary oxalate excretion, testic-
ular degeneration, neuropathy, mutagenicity, and changes in
the white matter of the central nervous system [175]; obviously
these findings make DCA unsuitable for extended use [196].
One would hope that the encouraging results of the human
studies coupled with those from experimental models would
prompt prospective controlled trials of this agent to define its
proper role in the management of lactic acidosis. In one sense,
augmentation of lactate utilization during lactic acidosis by
DCA resembles restoration by insulin of the disordered metabo-
lism during diabetic ketoacidosis. Although the underlying
disease is clearly the main determinant of the eventual outcome
of the patient, alleviation of the lactic acidemia by DCA or an
analogue coupled with judicious administration of alkali for
severe acidemia should at least allow the clinician the opportu-
nity to apply other therapeutic measures directed at the inciting
disorder. It is currently unknown whether the beneficial effect
of DCA on lactic acidosis would be translated into a favorable
alteration of the natural course of the underlying disease and
thus to decreased mortality. Indeed, the so-far disappointing
survival data with DCA therapy should restrain the critics of
NaHCO3 therapy who have denounced bicarbonate therapy on
the charge that high mortality rates from lactic acidosis persist
despite alkali provision.
Conclusion
Advances in the understanding of lactate metabolism have
allowed insights into the pathogenesis of lactic acidosis. Despite
this progress, however, the development of hyperlactatemia
remains an index of the gravity of the patient's condition and is
commonly the harbinger of the patient's impending demise. The
mainstay of therapy for lactic acidosis continues to center
around efforts to improve or eradicate the underlying cause or
predisposing condition, coupled with the careful and restrained
administration of sodium bicarbonate to prevent or treat critical
acidemia. Clinical research should continue with the promising
investigational agent DCA to define its proper role in the
treatment of the various forms of lactic acidosis.
Questions and answers
DR. JOHN T. HARRINGTON: You alluded to the hyperlactate-
mia of respiratory alkalosis. Could you be a little more quantita-
tive on this issue?
DR. MADIAS: Several investigators have attributed a major
component of the reduction in plasma bicarbonate during acute
respiratory alkalosis to the accumulation of lactic acid (on the
order of 50% to 75%). This conclusion was based on studies in
anesthetized animals subjected to mechanical ventilation suffi-
cient to achieve severe hypocapnia (PaCO, less than 15 mm Hg)
[18, 197, 198]. By contrast, studies in unanesthetized animals
and in humans subjected to milder degrees of hypocapnia
(PaCO, of 20 to 30 mm Hg) have reported only a slight and
short-lived elevation in plasma lactate concentration (in the
range of 0.5 to 1.5 mEq/liter). Indeed, the hyperlactatemia
vanishes within 8 hours despite the persistent hypocapnia [23,
24, 28]. Additional studies in anesthetized animals and humans
confirm the presence of only a mild degree of hyperlactatemia
during moderate grades of acute respiratory alkalosis [22, 25—
271. Moreover, during chronic hypocapnia, plasma lactate
concentration is within normal limits even in the presence of
associated hypoxemia [29—34]. The large increase in lactate
observed by some probably reflected a degree of circulatory
insufficiency consequent to the cardiovascular effects of anes-
thesia and vigorous mechanical ventilation.
DR. VINCENT J. CANzANELLO (Division of Nephrology,
NEMCH): Do changes in hormones affecting the transcellular
distribution of potassium account for the lack of hyperkalemia
during experimental lactic acidosis?
DR. MAmAs: To my knowledge, this attractive possibility has
not been investigated systematically. In this regard, recent
observations have uncovered a role of the endocrine pancreas
to account for the different response of plasma potassium to
experimental ketoacidosis (normokalemia or hypokalemia) as
compared to mineral acidosis (hyperkalemia): Whereas ketoaci-
dosis was associated with hyperinsulinemia, HC1-induced aci-
dosis was accompanied by elevated glucagon levels [199].
DCA OCA
Ii
a-
Cu
—8<8
60
50
40
30
0 1 2 3 4 5 6 7 8 9 10 11 15 16 17 20
Lactic acidosis 769
Da. RICHARD L. TANNEN (Director, Division of Nephrology,
the University of Michigan Medical Center, Ann Arbor, Michi-
gan): Dr. Madias, I agree with your comments and your
recommendations about bicarbonate administration in patients
with acute lactic acidosis. However, in considering the adverse
effects on the circulation that clearly have been shown to attend
treatment with bicarbonate in studies of experimental lactic
acidosis [49, 51], I would like to propose that factors other than
bicarbonate itself or changes in the hydrogen ion concentration
might be at fault. It seems quite possible, for example, that
these adverse effects might be caused by metabolic intermedi-
ates, the concentrations of which are stimulated by the adminis-
tration of bicarbonate.
DR. MADIAS: I agree that changes in acid-base status conse-
quent to bicarbonate administration cannot explain the adverse
hemodynamic effects reported in these studies [49, 51, 96, 103].
These reports have implied that the hemodynamic deterioration
might arise from bicarbonate-induced intracellular acidosis. But
this suggestion runs counter to available experimental evi-
dence. First, whole-body intracellular pH increases following
sodium bicarbonate infusion in the dog [200]. Second, cardiac
and skeletal muscle intracellular pH of the rabbit increases in
response to sodium bicarbonate infusion [201]. Moreover,
myocardial contractility and cardiac output increase consistent-
ly following an intravenous or intracoronary infusion of sodium
bicarbonate in the dog [112, 202, 203]. Your suggestion that one
or more metabolic intermediates of stimulated glycolysis might
be at fault is an attractive one and deserving of future
investigation.
I should like to reemphasize the important insights in the
physiology of lactic acid metabolism that these studies have
provided [47—51]. The findings on the hemodynamic effects of
bicarbonate treatment have raised important questions that
merit further investigation. On the other hand, I maintain
strongly at present that any extrapolation from the findings of
these studies to patients is inappropriate. I have presented in
detail the reasons for my position, chief of which are the
questionable relevance of the experimental models to the
clinical circumstances and the strong evidence indicating that
severe acidemia triggers a series of adverse hemodynamic
effects. I should add that regarding mortality, even no treatment
at all appears to make no difference in these experimental
models [49, 51]. I suggest that leaving severe lactic acidosis
untreated is not a viable option in the clinical setting.
DR. ANDREW S. LEVEY (Division of Nephrology, NEMCH):
Could you expand your comments about the potential toxicity
of the lactate ion itself?
DR. MADIAS: Our thinking has been dominated by the
concept that the deleterious effects of lactic acidosis stem
exclusively from the outpouring of hydrogen ions into the body
fluids, whereas the lactate ions themselves are thought to be
innocuous. Yet, some [170—173] but not all [147] of the recent
pieces of evidence I have reviewed cast doubt on this concept
and argue for a direct adverse effect of the lactate ion on
myocardial contractility. I believe that this may be an issue of
great importance, and it certainly warrants intensive
investigation.
DR. CANZANELLO: A number of recent studies suggest that
administration of either NH4C1 or NaHCO3 induces a substan-
tial decrease or rise, respectively, of the hyperlactatemia of
exercise. Have these maneuvers affected exercise tolerance?
DR. MADIAS: Careful studies have documented that treat-
ment with oral NH4C1 is associated with markedly diminished
endurance during high-intensity, cycle-ergometer exercise; by
contrast, treatment with oral NaHCO3 led to enhanced endur-
ance [41, 204, 205]. In contrast to these studies of prolonged
exercise, changes in acid-base status induced by these maneu-
vers have not produced appreciable effects on maximal power
output and fatigue during short-term, maximal exercise [39]. In
both types of exercise however, NH4C1-induced acidosis has
decreased the post-exercise plasma lactate concentration,
whereas NaHCO3 has augmented the hyperlactatemia. In addi-
tion to inducing changes in net lactate production, alterations in
acid-base status probably influence plasma lactate levels by
affecting the rate of lactate efflux from muscle; several observa-
tions suggest that acidosis impairs and alkalosis promotes the
effiux of lactate [206—2081.
DR. RONALD D. PERRONE (Division of Nephrology,
NEMCII): Would you comment on the treatment of the lactic
acidosis associated with malignancies?
DR. MADIAs: Although lactic acidosis in the company of
circulatory insufficiency, liver failure, or sepsis is a common
occurrence in the preterminal stage of many neoplastic dis-
eases, it occasionally develops in the absence of such factors
and may pursue a relatively chronic course [3, 4, 65]. Such a
"paraneoplastic" metabolic derangement usually is seen in
patients with leukemia or other myeloproliferative disorders; it
also occurs in association with lymphomas and with several
solid tumors. Overproduction of lactic acid by the neoplastic
tissue has been implicated in the pathogenesis of this syndrome.
Because leukocytes and neoplastic cells have a high glycolytic
rate, increased production of lactate would be expected if the
tumor burden were large. In some instances, lactic acidosis has
developed only in association with high-glucose, total parenter-
al nutrition. In addition, rapidly proliferating tumors may suffer
from an inadequate blood supply, producing severe hypoxia
and an increased dependence on anaerobic glycolysis. Also,
oxygenation can be decreased in a tightly packed bone marrow,
thus favoring the accumulation of lactate. The pathogenetic role
of lactate overproduction is supported by the observation that
lactic acidosis resolves with successful treatment of the under-
lying malignancy [209—2111. Furthermore, a role for hepatic
underutilization of lactate has been suggested in some cases of
lactic acidosis in patients with massive replacement of the liver
by tumor [3, 4, 65, 2111.
With regard to alkali administration, the general restraint I
suggested for its use in hypoxic states should be exercised also
in this setting, As I have mentioned, even massive doses of
alkali may not succeed in substantially increasing plasma bicar-
bonate in these patients because of a direct stoichiometric
relationship between alkali administration and acid production,
presumably by the malignancy [43, 44]. In addition to the well-
known risks stemming from the administration of large bicar-
bonate loads, aggravation of the prevailing cachexia may also
occur in the patient with cancer and poor dietary intake because
the body's glycogen and protein stores may be depleted as a
consequence of stimulated lactate production [44]. Consequent-
ly, such patients should receive the smallest possible amount of
bicarbonate that is sufficient to prevent or treat life-threatening
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acidemia and always in the company of an adequate nutrient
supply.
DR. HARRINGTON; What is your opinion regarding the phe-
nomenon referred to as idiopathic lactic acidosis?
DR. MADrAS: As you know, the terms "idiopathic" and
"spontaneous" have been applied to cases of lactic acidosis
that develop presumably in the absence of evidence for an
established cause or associated condition [1, 2, 212]. Although
as yet unrecognized cause(s) may be at play, well-founded
reservations have been raised about the validity of this designa-
tion [4, 213]. Close scrutiny of published reports suggests that
many such patients probably suffered from circulatory insuffi-
ciency too subtle for clinical detection [135, 213, 214]. In
addition, a substantial fraction of patients classified as having
"idiopathic" lactic acidosis were taking phenformin. Indeed, in
the great majority of cases, the clinical picture quickly ad-
vanced to overt circulatory collapse, often in the company of
sepsis or liver failure, and had a catastrophic outcome [4, 215,
216]. It therefore appears that the development of so-called
idiopathic lactic aeidosis is usually a warning sign presaging the
appearance of circulatory failure. Although I have included it in
Table 3 for completion, I suspect that idiopathic lactic acidosis
does not exist.
Reprint requests to Dr. N. P. Madias, Division of Nephrology, Box
172, New England Medical Center, 17] Harrison Avenue, Boston,
Massachusetts 02111, USA
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